Integrated BioTherapeutics Inc. and Integral Molecular Collaborate to Engineer Broadly Protective Ebolavirus Vaccines
Next-generation vaccine design strategies to protect against Ebola and related
Integrated BioTherapeutics Inc. Awarded $16.3M Contract from the National Institute of Allergy and Infectious Diseases to Develop a Treatment for Marburg Virus Disease
Contract to support manufacturing and a Phase 1 clinical trial
Gary Nabors, Ph.D. Joins Integrated BioTherapeutics Inc. as Executive Vice President and Chief Development Officer
IBT is pioneering the development of the first multivalent toxoid-based
Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines and provides strategic update
Copenhagen, Denmark, 06 January 2020 - Today, the Novo Holdings REPAIR Impact Fund
CARB-X FUNDS INTEGRATED BIOTHERAPEUTICS TO EXPAND THE DEVELOPMENT OF ITS STAPHYLOCOCCUS AUREUS VACCINE TO FACILITATE USE IN THE DEVELOPING WORLD
Freeze-dried version of vaccine would boost availability to the world,
IBT Receives Phase II STTR grant from NIAID for development of Novel ISTAb therapeutics for B. anthracis
IBT in collaboration with Dr. Daniel Nelson’s lab at University
IBT Receives Phase I SBIR grant from NIAID for development of monoclonal antibodies against Marburg Virus using a novel discovery platform
IBT in collaboration with the laboratory of Dr. Brandon Dekosky,
IBT Receives Phase I SBIR grant from NIAID for development of monoclonal antibodies against Marburg Virus using a novel discovery platform
IBT in collaboration with the laboratory of Dr. Brandon Dekosky,
IBT Receives Phase I/II Fast Track SBIR grant from NIAID for development of broadly protective monoclonal antibodies against Influenza Virus
IBT in collaboration with Abviro, LLC (Bethesda, MD) received a
IBT Receives Phase I SBIR grant from NIAID for development of Novel ISTAb therapeutics for Staph aureus
IBT in collaboration with Dr. Jean Lee lab at Brigham
